Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2,286

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Breast Cancer Statistics, 2022

Open access
Giaquinto, Angela N., Sung, Hyuna, Miller, Kimberly D., Kramer, Joan L., Newman, Lisa A., Minihan, Adair, Jemal, Ahmedin, Siegel, Rebecca L.·2022·CA: A Cancer Journal for Clinicians

Abstract

This article is the American Cancer Society’s update on female breast cancer statistics in the United States, including population‐based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010–2019), the rate increased by 0.5% annually, largely driven by localized‐stage and hormone receptor‐positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989–2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016–2020) and two‐fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5‐year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black–White gaps in absolute terms for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative disease (88% vs. 96%), hormone receptor‐negative/human epidermal growth factor receptor 2‐positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high‐quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3322/caac.21754

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 11

  1. Centers for Disease Control and Prevention, 2019, Behavioral Risk Factor Surveillance System Survey Data 2019
  2. 10.1002/cncr.32472 · doi:10.1002/cncr.32472
  3. 10.1158/1055-9965.EPI-20-1528 · doi:10.1158/1055-9965.epi-20-1528
  4. Hamilton BE, 2022, Births: Provisional Data for 2021. Vital Statistics Rapid Release Report No. 20. Division of Vital Statistics, National Center for Health, Statistics
  5. 10.1016/j.jamcollsurg.2019.12.004 · doi:10.1016/j.jamcollsurg.2019.12.004
  6. 10.1002/jso.25315 · doi:10.1002/jso.25315
  7. 10.1001/jamasurg.2020.0322 · doi:10.1001/jamasurg.2020.0322
  8. 10.1016/j.semradonc.2022.01.004 · doi:10.1016/j.semradonc.2022.01.004
  9. 10.1245/s10434-018-6531-5 · doi:10.1245/s10434-018-6531-5
  10. 10.1001/jamasurg.2018.5113 · doi:10.1001/jamasurg.2018.5113
  11. American Cancer Society. Table 6B. Up‐to‐Date Mammography Prevalence (%) by State US 2020.Cancer Prevention & Early Detection Facts & Figures Tables and Figures 2022. American Cancer Society; 2022:32. Accessed July 1 2022.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/cancer‐prevention‐and‐early‐detection‐facts‐and‐figures/cped‐2022‐tables‐and‐figures.pdf

Cited by

See all 2,286

Metadata

Authors
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L.
Venue
CA: A Cancer Journal for Clinicians
Publisher
Wiley
Published
2022-10-03
Volume
72
Issue
6
Pages
524-541
ISSN
  • 0007-9235 (ISSN-L)
  • 1542-4863
OpenAlex
W4300690596
Cited by
2,286
References
90
FWCI
190.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.